We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells.
- Authors
Gomyo, Yoshihito; Sasaki, Ji-ichiro; Branch, Cynthia; Roth, Jack A; Mukhopadhyay, Tapas
- Abstract
Treating lung cancer cell lines using low-dose 5-aza-2'-deoxycytidine (DAC) caused an accumulation of procaspase-9 through mRNA upregulation, but the cells did not undergo apoptosis. However, when cells were treated with DAC and infected with a low dose of a recombinant wild-type p53 adenovirus vector (Ad-p53), a synergistic growth inhibitory effect was observed. Combination treatment induced Apaf-1 and procaspase-9 expression in which cytochrome c releases by Ad-p53 triggered the mitochondrial pathway of apoptosis. Selective blockage of caspase-9 activities by Z-LEHD-FMK completely attenuated DAC-induced enhancement of apoptosis mediated by Ad-p53 infection, and ectopic overexpression of procaspase-9 sensitized cells to Ad-p53-induced apoptosis in p53-null cells. In addition, DAC sensitized lung cancer cells to cisplatin and paclitaxel. Induction of the mitochondrial pathway of apoptosis using a slightly toxic dose of DAC may therefore be a strategy for treating lung cancer, and DAC treatment may have clinical implications when combined with chemotherapy or apoptosis-inducing gene therapy.Oncogene (2004) 23, 6779-6787. doi:10.1038/sj.onc.1207381 Published online 26 July 2004
- Subjects
LUNG cancer; CANCER cells; CELL lines; APOPTOSIS; GENE expression; CANCER treatment
- Publication
Oncogene, 2004, Vol 23, Issue 40, p6779
- ISSN
0950-9232
- Publication type
Abstract
- DOI
10.1038/sj.onc.1207381